Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Clinicians and patients need updated evidence on the comparative effectiveness and safety of diabetes medications to make informed treatment choices. PURPOSE: To evaluate the comparative effectiveness and safety of monotherapy (thiazolidinediones, metformin, sulfonylureas, dipeptidyl peptidase-4 [DPP-4] inhibitors, sodium-glucose cotransporter 2 [SGLT-2] inhibitors, and glucagon-like peptide-1 [GLP-1] receptor agonists) and selected metformin-based combinations in adults with type 2 diabetes. DATA SOURCES: English-language studies from MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, indexed from inception through March 2015 (MEDLINE search updated through December 2015). STUDY SELECTION: Paired reviewers independently identified 179 trials and 25 observational studies of head-to-head monotherapy or metformin-based combinations. DATA EXTRACTION: Two reviewers independently assessed study quality and serially extracted data and graded the strength of evidence. DATA SYNTHESIS: Cardiovascular mortality was lower for metformin versus sulfonylureas; the evidence on all-cause mortality, cardiovascular morbidity, and microvascular complications was insufficient or of low strength. Reductions in hemoglobin A1c values were similar across monotherapies and metformin-based combinations, except that DPP-4 inhibitors had smaller effects. Body weight was reduced or maintained with metformin, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors and increased with sulfonylureas, thiazolidinediones, and insulin (between-group differences up to 5 kg). Hypoglycemia was more frequent with sulfonylureas. Gastrointestinal adverse events were highest with metformin and GLP-1 receptor agonists. Genital mycotic infections were increased with SGLT-2 inhibitors. LIMITATION: Most studies were short, with limited ability to assess rare safety and long-term clinical outcomes. CONCLUSION: The evidence supports metformin as first-line therapy for type 2 diabetes, given its relative safety and beneficial effects on hemoglobin A1c, weight, and cardiovascular mortality (compared with sulfonylureas). On the basis of less evidence, results for add-on therapies to metformin were similar to those for monotherapies. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compounds that modulate NF-κB signalling, including metformin137,235–237, apigenin238, kaempferol238 and BAY 11–7082 (REF.118), have also been shown to decrease SASP production.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [236]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“We evaluated the heterogeneity among the trials by using the I(2) statistic (11).”
MethodMeta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“We generated summary treatment effects with the random-effects model estimated by using the DerSimonian and Laird method in settings of low heterogeneity (I(2) < 50%) (12) and the profile likelihood estimate in settings of high heterogeneity (I(2) ≥ 50%) (13).”
MethodAssessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · cited 1×
“Two independent reviewers assessed risk of bias in individual RCTs by using the criteria of Jadad and colleagues (9), as in our prior review (6).”
MethodDowns, S. H., & Black, N. (1998) · Journal of Epidemiology and Community Health · doi:10.1136/jech.52.6.377 · Cited by 8,252 · cited 1×
“We used the Downs and Black tool for assessment of the risk of bias for the nonrandomized trials and observational studies (10).”
MethodEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“diet) on the relative benefits of metformin and sulfonylureas for the spectrum of long-term outcomes important in diabetes (32).”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Research works printed but not linked: 1
- Wang CP, 2014, J Endocrinol Diabetes Obes, 2
Cited by
Items 501–600 of 733
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus
Barry, M. J., Humphrey, L. L., & Qaseem, A. (2017) · Annals of Internal Medicine · doi:10.7326/l17-0234 · Cited by 3
Risk factors for fasting blood glucose control in middle-aged and elderly type 2 diabetes patients
Kuang, N.-Y., Ye, H., Chen, J.-P., Li, H., & Tang, N. (2024) · Medicine · doi:10.1097/md.0000000000039322 · Cited by 2
Rusli, R., Nurisyah, N., Dewi, S. T. R., Salasa, A. M., Arisanty, A., Ramadhan, D. S. F., Adhayanti, I., & Chen, H. W. J. (2025) · Pharmacia · doi:10.3897/pharmacia.72.e139314 · Cited by 2
Phakeenuya, V., Phusantisampan, T., & Sriariyanun, M. (2025) · Applied Science and Engineering Progress · doi:10.14416/j.asep.2025.09.002 · Cited by 2
Vempati, R., Damarlapally, N., Roy, P., Mylavarapu, M., Vasudevan, S. S., Reguram, R., Vora, T., Jain, H., Ahmed, R., & Krishnamoorthy, G. (2025) · Diagnostics · doi:10.3390/diagnostics15182288 · Cited by 2
Turhan, B., Sağlam, S., Yücel, M. O., Dalaslan, R. E., Sungur, M. A., Demir, F., Karaduman, Z. O., & Arıcan, M. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1703958 · Cited by 2
Zhang, W., Ren, L., Du, J., Sun, R., Zhao, W., Song, X., Jiang, S., Wang, Z., & Wang, W. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1737337 · Cited by 2
Peng, Y., Sun, C., Wang, Z., & Fan, X. (2026) · Chinese Medicine · doi:10.1186/s13020-026-01374-4 · Cited by 2
Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
Moon, M. K. (2018) · Journal of Korean Diabetes · doi:10.4093/jkd.2018.19.1.23 · Cited by 2
Perfil da prescrição de medicamentos para o diabetes mellitus tipo 2 de um município paulista
Ueta, J. M., Cavalheiro, S. F. L., Carbi, A. D. O., Takata, D. Y., Franco, L. J., & de Oliveira, R. E. M. (2018) · Ciência & Saúde · doi:10.15448/1983-652x.2018.2.29288 · Cited by 5
“Grupo etário (anos) 30-39 4 (2,7) 3 (75) 1 (25) Referência 40-49 20 (13,3) 17 (85) 3 (15) 0,52 (0,04; 6,94) 50-59 26 (17,3) 22 (84,6) 4 (15,4) 0,54 (0,04; 6,65) 60-69 33 (22,0) 24 (72,7) 9 (27,3) 1,12 (0,10; 12,26) 70-79 34 (22,7) 20 (58,8) 14 (41,2) 2,1 (0,19; 22,32) 80-89 30 (20,0) 25 (83,3) 5 (16,7) 0,6 (0,05; 7,01…”
Maleš, V. K., & Požar, M. (2021) · ACS Omega · doi:10.1021/acsomega.1c01744 · Cited by 2
Evergreened drugs or evergreened profits?
Siddalingaiah, S., & Fugh‐Berman, A. (2022) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13695 · Cited by 2
Börklü, E. (2023) · Yeast · doi:10.1002/yea.3845 · Cited by 2
“Metformin, on the other hand, is an FDA‐approved first‐line agent to treat type 2 diabetes (Maruthur et al., 2016), with copper‐chelating properties (Logie et al., 2012).”
BackgroundÖzalp, Y., Hourani, O. M., Chunu, J. T., Yeğen, G., & Aksu, N. B. A. B. (2023) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.1168 · Cited by 2
Treatment Approaches and Challenges
Malboosbaf, R., & Hatami, N. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815196535123010005 · Cited by 2
Pandya, N., & Patel, M. (2024) · Springer eBooks · doi:10.1007/978-3-030-74720-6_38 · Cited by 2
Ianus Bifrons: The Two Faces of Metformin
Goglia, U., Hasballa, I., Teti, C., Boschetti, M., Ferone, D., & Albertelli, M. (2024) · Cancers · doi:10.3390/cancers16071287 · Cited by 3
“Bodyweight and LDL cholesterol were reduced with metformin over 3 years of treatment, and eGFR was increased.”
BackgroundKhunlertkit, T., Viangteeravat, T., Wangprapa, P., Siriwechdaruk, S., Ford, J. M., & Pongpirul, K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302438 · Cited by 2
Tong, J., Li, X., Liu, T., & Liu, M. (2024) · Science Progress · doi:10.1177/00368504241262116 · Cited by 2
Metformin: Its salutary effects beyond diabetes mellitus
Sawalha, K., Gautam, N., Sivakumar, K., Paydak, H., & Mehta, J. L. (2025) · Journal of Investigative Medicine · doi:10.1177/10815589251327511 · Cited by 4
Biological and Biosimilar Medicines in Contemporary Pharmacotherapy for Metabolic Syndrome
Górecka, W., Berezovska, D., Mrozińska, M., Nowicka, G., & Czerwińska, M. E. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060768 · Cited by 2
“The comparison of SGLT-2 and metformin indicated that in the cases of genital mycotic infections, metformin is favored [124].”
Kawazu, S., Kanazawa, Y., Iwamoto, Y., Katayama, S., Origasa, H., & Kuzuya, T. (2017) · Diabetology International · doi:10.1007/s13340-017-0319-x · Cited by 2
Antidiabetic Medication in Patients with Chronic Kidney Disease: What's New?
Dominijanni, S., Cipriani, S., Malaguti, M., Triolo, L., Ansali, F., & Floccari, F. (2017) · Nephrology Point of Care · doi:10.5301/napoc.5000210 · Cited by 4
Dubois, T. B., Simpson, S. H., & Eurich, D. T. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.09.002 · Cited by 2
Metformin in the Era of New Antidiabetics
Al-Mahdi, E. A. R., Barrios, V., & Zamorano, J. L. (2021) · Future Cardiology · doi:10.2217/fca-2020-0195 · Cited by 2
Arai, K., Nishikawa, T., Shirabe, S., Matsuzawa, Y., Ohtsu, S., Yuasa, S., Hirao, K., & Mori, H. (2021) · Diabetology International · doi:10.1007/s13340-021-00520-7 · Cited by 3
Common systemic medications that every optometrist should know
Williams, R. M., & Hui, A. (2021) · Clinical and Experimental Optometry · doi:10.1080/08164622.2021.1945409 · Cited by 2
“glycaemic efficacy, and low risk of weight gain and hypoglycaemia.(23) Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity.”
BackgroundDiabetes Mellitus type 2: Management and follow up in Primary Health Care Center
Alkinani, A. A., Alkhrizi, I. M., Alkathiri, S. H., Alzubaidi, H. L. A., Alghanmi, A. A., Alghanmi, A. M., Alnashri, I. A., & Alruwaili Amal Muhaysin, B. (2021) · Archives of Pharmacy Practice · doi:10.51847/mvmt9sdifp · Cited by 4
GLP-1Ra en el manejo de diabetes mellitus tipo 2: una revisión de revisiones sistemáticas
Cantor-Cruz, F., Gomez, O., Mendivelso, F., Ruiz, P. C., Rincón, O., Yama-Mosquera, E., Moscoso-Martínez, E. A., Villamizar, L. F. B., González, C. A., Acevedo, J. R., et al. (2022) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.9.2.601 · Cited by 2
Tratamento do Diabetes Mellitus
Rosa, R. R. P. A. (2022) · Revista Saúde em Foco · doi:10.12819/rsf.2022.9.1.5 · Cited by 3
Ma, Z., Wang, H., Shan, S., Zhu, K., & Yuan, L. (2023) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2023.100566 · Cited by 2
Abdelmoaty, H., Good, S., & Phan, T. Đ. (2024) · World Journal of Oncology · doi:10.14740/wjon1590 · Cited by 2
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_44 · Cited by 4
Diabetes and cardiovascular disease
Guamán, C., Acosta, W. S., Alvarez, C., & Hasbum, B. (2023) · Cardiac and Cardiovascular Research · doi:10.54517/ccr.v4i2.1918 · Cited by 2
Complementary Efforts Make for Efficient Research
Selby, J. V. (2016) · Annals of Internal Medicine · doi:10.7326/m16-0869 · Cited by 2
Glycemic Therapy for Type 2 Diabetes: Choices Expand, Data Lag Behind
FRADKIN, J. E., & Rodgers, G. P. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2883 · Cited by 2
“The new guideline is based on a systematic review (2) of comparative effectiveness research (CER) and thus does not use data from the cardiovascular outcomes trials (CVOTs) mandated by the U.”
BackgroundMethodSGLT-2 Inhibitors and Renal Outcomes in Non-Diabetic Patients: A Systematic Review
Sousa, M., Almeida, C., Marchão, N., Godinho, I., Lopes, J. A., & Gameiro, J. (2023) · Portuguese Journal of Nephrology & Hypertension · doi:10.32932/pjnh.2023.03.234 · Cited by 3
Kondlo, B., Cassimjee, Z., Olivier, C., & Bayat, Z. (2024) · Wits Journal of Clinical Medicine · doi:10.18772/26180197.2024.v6n1a2 · Cited by 1
Delbaere, J., Deboever, E., Vaes, B., Nobels, F. R. E., Mamouris, P., & Goderis, G. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.09.003 · Cited by 1
Cai, X., Ji, L., Yuan, M., Ma, J., Bian, F., Li, S., Pang, W., Yan, S., Zhou, H., Hou, M., et al. (2024) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2024.101197 · Cited by 1
“18 – 20 Meanwhile, treatment/study withdrawal was only in 1.6% of patients related to the study drug GI AEs.”
BackgroundInfluentialAndhale, A. V. (2024) · African Journal of Biomedical Research · doi:10.53555/ajbr.v27i3.5772 · Cited by 1
Future Perspectives in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_6 · Cited by 2
Mathematical analysis of nonlinear combination drug delivery
Shi, J., & Xiang, Z. (2025) · Electronic Research Archive · doi:10.3934/era.2025082 · Cited by 1
Deprescribing sulfonylureas in patients over the age of 65 within the Boise VA Medical Center
Everett, N., Cruz, R., Ertle, L., & Nguyen, E. (2025) · JAPhA Practice Innovations · doi:10.1016/j.japhpi.2025.100051 · Cited by 2
Kavitha, S. K., Anandabaskar, N., Navabalan, V., Manickam, S., Dhamodharan, A., & Subramanian, G. (2025) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_46_25 · Cited by 1
“[5] Notably, recent data suggest a declining trend in the use of sulfonylureas and a shift away from dual therapy combining metformin and sulfonylureas over the last 15 years.”
Thopireddy, L., Yarrappagaari, S., Benne, L., Seethamma, G., Tenkayala, S. R., & Saddala, R. R. (2025) · International Journal of Ayurvedic Medicine · doi:10.47552/ijam.v16i3.5888 · Cited by 1
Real-World Evidence for Metformin Use in Solid Organ Transplant Recipients Living With Diabetes
Dotan, I., Kushnir, S., Shochat, T., & Diker‐Cohen, T. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.11.006 · Cited by 1
Cline, L., & Wilson, E. (2026) · Physician Assistant Clinics · doi:10.1016/j.cpha.2025.09.002 · Cited by 1
Ferrari, L. F., Wilkinson, A., Ramirez, A., Kuchenbecker, J. A., Neitz, J., Mauck, M., & Taylor, N. E. (2025) · Pain · doi:10.1097/j.pain.0000000000003883 · Cited by 1
Zhang, H. B., Yan, Y., Pang, J. P., Kong, M. T., & Zhu, Q. (2026) · OncoTargets and Therapy · doi:10.2147/ott.s572872 · Cited by 1
Jimoh, A. O., Hudu, S. A., Sabir, A. A., Adamu, A. A., Bello, N., Tahir, A., & Abubakar, N. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/8464330 · Cited by 1
Kumar, D., Bhatty, S. A., Kashif, S. M., & Kumar, P. (2026) · Pakistan Armed Forces Medical Journal · doi:10.51253/pafmj.v76i2.12228 · Cited by 1
Nawaz, M., Afzal, A., Ahmad, I., Shah, H., Nawaz, S., Shafique, A., Cai, Y., Sarfraz, M., & Madni, A. (2026) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-026-03415-z · Cited by 1
In Vivo Evaluation of Antidiabetic Activity of Erythroxylum coca in Rats
Mishra, R., Prajapati, P., & Jain, V. (2026) · Journal of Natural Remedies · doi:10.18311/jnr/2026/55133 · Cited by 1
Peng, H., Jiang, J., Wang, Z., & Wang, W. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-02201-y · Cited by 1
Bringing patient centricity to diabetes medication access in Canada
Glennie, J. L., Burns, K. K., & OH, P. I. (2016) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s116570 · Cited by 1
Rhee, S. Y. (2018) · Journal of Korean Diabetes · doi:10.4093/jkd.2018.19.1.15 · Cited by 1
Dehghan, H., Mirzaei, M., Mirzaei, E., Asl, E. M., Ataiy, A., & Mirzaei, M. (2018) · مجله دانشگاه علوم پزشکی اردبیل · doi:10.29252/jarums.18.1.21 · Cited by 1
de Oliveira, R. E. M., da Silva, A. S., Ueta, J. M., & Franco, L. J. (2018) · Clinical & Biomedical Research · doi:10.4322/2357-9730.77241 · Cited by 2
Atherosclerosis and Diabetic Nephropathy
Duivenvoorden, R. (2018) · Springer eBooks · doi:10.1007/978-3-319-93521-8_22 · Cited by 3
Jasaputra, D. K., Wargasetia, T. L., & Elizabeth, E. (2019) · Global Medical & Health Communication (GMHC) · doi:10.29313/gmhc.v7i1.2917 · Cited by 1
“5 g/kgBW for 14 weeks; (5) Diabetes ingredients infusion A group, rats were given a hypercaloric diet for 8 weeks, then hypercaloric diet+DI infusion (green chiretta, Java tea, and bitter grape = 1:1:2) dose of 0.”
MethodDrugs for Treatment of Diabetes Mellitus
Seifert, R. (2019) · Springer eBooks · doi:10.1007/978-3-030-18899-3_19 · Cited by 1
Radhi, M. M., Al-Hayani, M. J., & Tareef, M. F. (2019) · Epitoanyag-Journal of Silicate Based and Composite Materials · doi:10.14382/epitoanyag-jsbcm.2019.16 · Cited by 1
“In the pharmacy market it is traded under the name of Glucophage and it is used as a treatment of type 2 diabetes,[7,8] particularly for people who are overweight, has polycystic ovary syndrome, cardiovascular disease or cancer complications of diabetes [9,10].”
BackgroundNoninsulin Therapy for Diabetes
Maxson, R., & McCoy, E. K. (2020) · Physician Assistant Clinics · doi:10.1016/j.cpha.2019.11.005 · Cited by 1
Is Metformin a Treatment Opportunity for Colorectal Cancer?
Eroglu, E., & Uzun, Ö. (2020) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2020/172 · Cited by 1
Management of type 2 diabetes without insulin: An update for the PCP
Thiruvengadam, S., & Peter, P. R. (2021) · Disease-a-Month · doi:10.1016/j.disamonth.2021.101290 · Cited by 1
Metformin-associated lactic acidosis (MALA) in a peritoneal dialysis patient
Kim, N. H. (2021) · Medical Biological Science and Engineering · doi:10.30579/mbse.2021.4.2.116 · Cited by 1
“Metformin considered as first-line medication for the treatment of type 2 diabetes [2].”
BackgroundPérez-Benítez, A., Ariza-Ramírez, J. L., Fortis-Valera, M., Arroyo-Carmona, R. E., la Luz, I. M.-D., Ramírez-Contreras, D., & Bernès, S. (2022) · IUCrData · doi:10.1107/s2414314622006277 · Cited by 1
Yang, Y., Hou, X.-Y., Wei-qing, G., Wang, X., Xu, Y., Chen, W., Tian, Y., Gao, H., & Chen, Q. (2022) · Personalized Medicine · doi:10.2217/pme-2022-0059 · Cited by 1
CT Image of Consolidation and Ground-Glass Opacification (GGO) of COVID-19 in Diabetic Patient
Ogura, K., Bando, H., Kato, Y., Yamashita, H., & Kato, Y. (2023) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2023/asjbccr.6299 · Cited by 1
Biryukova, E. V., & Kileynikov, D. V. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-156 · Cited by 1
Place of metformin in modern clinical guidelines for the treatment of type 2 diabetes mellitus
Моргунова, Т. Б., Glinkina, I. V., Дмитриевна, П. Е., Zorina, A. A., & Fadeev, V. V. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-211 · Cited by 2
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_44-2 · Cited by 1
Alatawi, A. M. (2023) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.40.1.6982 · Cited by 1
Recommandations pour des soins préventifs pour promouvoir l’équité en matière de santé
Persaud, N., Sabir, A., Woods, H., Sayani, A., Agarwal, A., Chowdhury, M., de Leon-Demare, K., Ibezi, S., Jan, S. H., Katz, A., et al. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.230237-f · Cited by 1
Zhang, D., Jung, Y., Seol, M., Zhou, S., Chaudhary, D., Jeong, J., & Kim, J. (2024) · Current Analytical Chemistry · doi:10.2174/0115734110288849240116045045 · Cited by 1
Yoshihara, H., Tonoike, T., Ohno, H., Nishiuchi, S., & Igarashi, A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01611-9 · Cited by 1
Borozdina, N. A., Popkova, D. V., & Dyachenko, I. A. (2024) · Биоорганическая химия · doi:10.31857/s0132342324040057 · Cited by 1
Morampudi, R. K., Neelakandan, V., Kumar, B. N., & Indla, E. (2024) · Cureus · doi:10.7759/cureus.75866 · Cited by 1
Munoz, S. R., Mol, P. G. M., de Vries, F., van Dijk, P. R., Hillege, H. L., Postmus, D., & de Vries, S. T. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s486553 · Cited by 1
Gallo, R. J., Lin, S., Fang, D. Z., Glassman, P. A., Sahay, A. P., & Heidenreich, P. A. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09384-y · Cited by 1
Reıd, I. O. A., Osman, S. M., & Bakheet, S. M. (2024) · Journal of Pharmacy and Allied Medicine · doi:10.58985/jpam.2024.v02i02.24 · Cited by 1
Moderne Antidiabetika in der Kardiologie
Schneider, C., & Pfister, R. (2018) · Aktuelle Kardiologie · doi:10.1055/a-0655-7407 · Cited by 1
“Metformin ist kardioprotektiv und gilt daher als die primäre Option bei kardiovaskulären Risikopatienten [2].”
BackgroundInfluentialOptimization of type 2 diabetes mellitus control in Egyptian patients
Ebid, A.-H., Mobarez, M. A., Ramadan, R. A., & Adel, M. (2020) · Clinical Diabetology · doi:10.5603/dk.2020.0059 · Cited by 2
“In comparison with sulfonylureas (SUs), metformin as firstline therapy has a good impact on target HbA1c, weight, and cardiovascular mortality [16].”
ResultRegulation of glucose transport in cardiomyocytes
Bowman, P. R. T. (2019) · Enlighten: Theses (The University of Glasgow) · doi:10.5525/gla.thesis.41002 · Cited by 2
Rezaie, Z., Taghizadeh‐Ghehi, M., & Kohneloo, A. J. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03119-8 · Cited by 1
“ADRs, specifically hypoglycemia, imprecise [2].”
A modern approach to glucose-lowering therapy in frail older people with type 2 diabetes mellitus
Abdelhafiz, A. H., Pennells, D., & Sinclair, A. J. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2044304 · Cited by 1
“In the SO phenotype metformin remains the preferred first-line agent due to its cardiovascular benefits, weight neutral effects and a potential positive effect on frailty [21,22].”
BackgroundBessa, A. H. F. D. B. E. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2023.tde-05062023-141557 · Cited by 2
Most add-on therapies to metformin have similar effects on HbA1c
Karagiannis, T., & Bekiari, E. (2016) · BMJ Evidence-Based Medicine · doi:10.1136/ebmed-2016-110515
Type 2 diabetes in children and its association with obesity
Cremonesini, L. (2017) · Independent Nurse · doi:10.12968/indn.2017.7.17
Sánchez, J. M. L. (2017) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2017.04.00107
Usage of metformin in patients with type 2 diabetes mellitus
Huang, W. (2016) · UTAS Research Repository · doi:10.25959/23240615
Pharmacodynamic Evaluation: Endocrinology
Naafs, M. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-56637-5_35-1
Pasha, M. H. (2017) · NORA - Norwegian Open Research Archives
Managing the Diabetic Kidney Patient
Maxson, R., & Lisenby, K. M. (2018) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2018.04.002
The effects of metformin on colorectal cancer growth and the involvement of the gut microbiome
Broadfield, L. A. (2018) · MacSphere (McMaster University) · doi:10.71548/9648
Gorb, Y. G., Strona, V. I., & Komir, I. (2019) · Ukraïnsʹkij žurnal medicini bìologìï ta sportu · doi:10.26693/jmbs04.01.008 · Cited by 2
Lee, S. M., Aboubechara, N., Niu, F., Ledesma, V. M., Patel, Y. A., Millares, M., & Hui, R. L. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.3.350
All-cause mortality in patients on sulfonylurea monotherapy
Wheeler, S., & Boyko, E. J. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.03.021
Metadata
- Authors
- Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S.
- Affiliations
- MetroHealth (US)
- From The Johns Hopkins University School of Medicine; The Johns Hopkins University Bloomberg School of Public Health; and Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore, Maryland, and Center for Health Care Research and Policy, MetroHealth/Case Western Reserve University; MetroHealth Medical Center; and Case Western Reserve University, Cleveland, Ohio.
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-06-07
- Volume
- 164
- Issue
- 11
- Pages
- 740-751
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2340898396
- Cited by
- 682
- References
- 66
- Citations by year
- 2026: 37 · 2025: 52 · 2024: 60 · 2023: 68 · 2022: 80 · 2021: 90 · 2020: 89 · 2019: 71 · 2018: 68 · 2017: 56 · 2016: 11
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Funders
- Agency for Healthcare Research and Quality (290-2012-00007-I)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, metformin, monotherapy, thiazolidinediones, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, cardiovascular mortality, glycemic control, HbA1c, weight loss, hypoglycemia, gastrointestinal adverse effects, genital mycotic infections, first-line therapy
- MeSH terms
- Adult, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Metformin, Comparative Effectiveness Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.